AIDS Therapy

VaxGen hopes AIDS vaccine trial results warrant FDA filing but skeptics abound

Published in Vaccine Weekly, February 19th, 2003

As the maker of what would be the first vaccine for AIDS prepares to release key test results, some stock traders are betting against its success. AIDS activists have been debating its merits for a decade.

The concern centers around the vaccine's effectiveness: Its manufacturers believe it could be beneficial even if it works for only one out of three who take it. Critics say that that's not nearly good enough, and may not be good at all.

VaxGen, Inc. has promised to release results of a last 5,400-person trial of its vaccine, known as AIDSVAX, before the end of March.

In recent weeks and months, short-sellers have taken control...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-02-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry